Table 2 Patient Disposition
| Â | Number (%) of Patients | |||
|---|---|---|---|---|
Naproxen/Esomeprazole Magnesium 250Â mg/20Â mg | Naproxen/Esomeprazole Magnesium 375Â mg/20Â mg | Naproxen/Esomeprazole Magnesium 500Â mg/20Â mg | Total | |
Enrolled | Â | Â | Â | 51 |
Not assigned treatment (eligibility criteria not fulfilled) | Â | Â | Â | 5 |
Assigned treatment | 4 | 20 | 22 | 46 |
-Received study drug | 4 (100) | 20 (100) | 22 (100) | 46 (100) |
-Completed study and received 6 mo of study drug | 3 (75.0) | 16 (80.0) | 17 (77.3) | 36 (78.3) |
-Discontinued prematurely | 1 (25.0) | 4 (20.0) | 5 (22.7) | 10 (21.7) |
-Adverse event | 1 (25.0) | 1 (5.0) | 2 (9.1) | 4 (8.7) |
-Lost to follow-up | 0 | 2 (10.0) | 0 | 2 (4.3) |
-Severe non-compliance with protocol | 0 | 1 (5.0) | 0 | 1 (2.2) |
-Withdrew consent | 0 | 0 | 3 (13.6) | 3 (6.5) |